GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002507 | Cervix | CC | tolerance induction | 9/2311 | 28/18723 | 5.02e-03 | 2.98e-02 | 9 |
GO:0045589 | Cervix | CC | regulation of regulatory T cell differentiation | 9/2311 | 28/18723 | 5.02e-03 | 2.98e-02 | 9 |
GO:0002699 | Cervix | CC | positive regulation of immune effector process | 43/2311 | 235/18723 | 5.13e-03 | 3.02e-02 | 43 |
GO:0050672 | Cervix | CC | negative regulation of lymphocyte proliferation | 19/2311 | 83/18723 | 5.25e-03 | 3.08e-02 | 19 |
GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
GO:0002716 | Cervix | CC | negative regulation of natural killer cell mediated immunity | 7/2311 | 19/18723 | 5.65e-03 | 3.25e-02 | 7 |
GO:0032945 | Cervix | CC | negative regulation of mononuclear cell proliferation | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
GO:00019147 | Cervix | CC | regulation of T cell mediated cytotoxicity | 11/2311 | 39/18723 | 6.13e-03 | 3.48e-02 | 11 |
GO:00300981 | Cervix | CC | lymphocyte differentiation | 63/2311 | 374/18723 | 6.21e-03 | 3.52e-02 | 63 |
GO:0001911 | Cervix | CC | negative regulation of leukocyte mediated cytotoxicity | 8/2311 | 24/18723 | 6.29e-03 | 3.54e-02 | 8 |
GO:0042130 | Cervix | CC | negative regulation of T cell proliferation | 16/2311 | 67/18723 | 6.51e-03 | 3.61e-02 | 16 |
GO:00109482 | Cervix | CC | negative regulation of cell cycle process | 51/2311 | 294/18723 | 7.35e-03 | 3.94e-02 | 51 |
GO:0002822 | Cervix | CC | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/2311 | 168/18723 | 8.00e-03 | 4.18e-02 | 32 |
GO:0045089 | Cervix | CC | positive regulation of innate immune response | 26/2311 | 131/18723 | 9.33e-03 | 4.66e-02 | 26 |
GO:19021073 | Cervix | CC | positive regulation of leukocyte differentiation | 30/2311 | 157/18723 | 9.56e-03 | 4.73e-02 | 30 |
GO:19037083 | Cervix | CC | positive regulation of hemopoiesis | 30/2311 | 157/18723 | 9.56e-03 | 4.73e-02 | 30 |
GO:0045066 | Cervix | CC | regulatory T cell differentiation | 9/2311 | 31/18723 | 1.04e-02 | 4.97e-02 | 9 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0461220 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa04612110 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0517017 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-G | SNV | Missense_Mutation | | c.648C>A | p.His216Gln | p.H216Q | P17693 | protein_coding | deleterious_low_confidence(0) | benign(0.031) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
HLA-G | SNV | Missense_Mutation | rs767964419 | c.593A>G | p.Asn198Ser | p.N198S | P17693 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.982) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-G | SNV | Missense_Mutation | novel | c.733N>A | p.Gly245Arg | p.G245R | P17693 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(1) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-G | insertion | Nonsense_Mutation | novel | c.68_69insCTTAAGAGCTTTGTGAGTCCTGTT | p.Trp23delinsCysLeuArgAlaLeuTerValLeuLeu | p.W23delinsCLRAL*VLL | P17693 | protein_coding | | | TCGA-A8-A07I-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
HLA-G | SNV | Missense_Mutation | novel | c.532N>A | p.Glu178Lys | p.E178K | P17693 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.997) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-G | SNV | Missense_Mutation | | c.256N>C | p.Glu86Gln | p.E86Q | P17693 | protein_coding | tolerated_low_confidence(0.32) | benign(0.006) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-G | SNV | Missense_Mutation | | c.258N>T | p.Glu86Asp | p.E86D | P17693 | protein_coding | tolerated_low_confidence(0.09) | benign(0.027) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-G | SNV | Missense_Mutation | | c.910N>T | p.Pro304Ser | p.P304S | P17693 | protein_coding | tolerated_low_confidence(0.66) | possibly_damaging(0.506) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-G | SNV | Missense_Mutation | | c.391N>A | p.Gly131Arg | p.G131R | P17693 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.997) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
HLA-G | SNV | Missense_Mutation | rs780775783 | c.316N>T | p.Arg106Cys | p.R106C | P17693 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.925) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3135 | HLA-G | EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | hmg coa reductase inhibitors | | |
3135 | HLA-G | EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | fluorouracil | FLUOROURACIL | |
3135 | HLA-G | EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | methotrexate | METHOTREXATE | 16906016,19088262 |
3135 | HLA-G | EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | capecitabine | CAPECITABINE | |